A PSEN1 genetic test looks for mutations in the presenilin-1 gene, the most common known cause of early-onset, inherited Alzheimer's disease. Carriers of PSEN1 mutations typically develop symptoms between ages 30 and 60, well before the age most dementia diagnoses occur, which is why the test matters most when symptoms start early or run in the family, according to a PMC review article on autosomal-dominant Alzheimer's. This article covers what the test costs, which insurance situations actually get it covered, and how to find the right person to order and interpret it. The short version: cost is modest, coverage depends heavily on your specific clinical picture, and genetic counseling is not optional paperwork — it is built into every major guideline and most insurance policies that cover this test.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Does PSEN1 Testing Actually Cost?
- When Will Insurance Cover the Test?
- Why Genetic Counseling Comes Before and After the Test
- Who Should Ask for This Test, and Who Shouldn't
- Frequently Asked Questions
What Does PSEN1 Testing Actually Cost?
Laboratory panel testing that covers PSEN1 along with the related genes APP and PSEN2 typically runs $300 to $1,000 per patient, most often landing near the lower end around $300, according to a Fall 2025 genetic-counseling presentation from UW Health. That range reflects the lab cost for the panel itself and does not include the genetic counseling visits that typically accompany it. Testing is usually ordered as a three-gene panel rather than PSEN1 alone, since APP and PSEN2 mutations cause the same early-onset familial pattern and are evaluated together.
A disease-causing variant turns up in only 60% to 80% of people tested for early-onset Alzheimer's, according to ARUP Laboratories' test directory — a negative result does not rule out a genetic cause, since some families carry mutations in genes not yet identified. The three genes also behave differently once a mutation is found. PSEN1 and APP mutations show complete penetrance, meaning essentially everyone who carries the mutation eventually develops the disease if they live long enough, while PSEN2 mutations show about 95% penetrance in people who reach a normal lifespan, per ARUP's test directory. That distinction matters for how a positive result should be discussed with a patient or family member.
When Will Insurance Cover the Test?
Coverage hinges on clinical criteria, not simply on having a family member with dementia. Major payers converge on a similar standard: testing is offered to symptomatic patients with dementia onset before age 65 who also have a family history of early-onset Alzheimer's, an unknown family history such as from adoption, or a relative with an already-confirmed mutation, according to policies from Blue Shield of California and FEP Blue. Some insurers draw the line even more specifically around how the result will be used.
Blue Cross NC's policy covers APP/PSEN1/PSEN2 testing chiefly when results will inform reproductive decisions for people who meet the family-history or early-onset criteria, but classifies testing done purely for general risk assessment or to screen asymptomatic adults as not medically necessary, according to Blue Cross NC's medical policy AHS-M2038. Highmark's commercial policy in Pennsylvania follows the same logic and adds a procedural requirement: testing for early-onset familial Alzheimer's is deemed medically necessary only when clinical criteria are met, and genetic counseling is required both before and after testing for a known familial mutation, per Highmark's Commercial Medical Policy L-175-004. A reader checking coverage should expect to answer questions about age of onset, documented family history, and what will be done with the result before an insurer approves the claim. A few practical checks before ordering:.
- Confirm the patient's age at symptom onset is documented as under 65, if that is the basis for the claim.
- Gather any known family history of early-onset Alzheimer's, including whether a relative has a confirmed PSEN1, PSEN2, or APP mutation.
- Ask the ordering clinician whether pre-test genetic counseling has been scheduled, since several policies require it as a condition of coverage.
Why Genetic Counseling Comes Before and After the Test
Every major clinical guideline treats genetic counseling as part of the test itself, not an optional add-on. The 2011 joint practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors states that testing for early-onset autosomal-dominant Alzheimer's should occur only alongside counseling from someone with relevant expertise, as summarized by Alzforum. The reasoning differs depending on who is being tested.
A person already showing symptoms is confirming a likely diagnosis, which has its own emotional weight but a different counseling focus than testing a healthy relative who wants to know their future risk. For that second group — asymptomatic at-risk relatives — the same guideline recommends following the pre- and post-test counseling protocol originally developed for Huntington's disease, according to Alzforum's summary, a protocol built around structured sessions before and after disclosure specifically because the result cannot be undone once known. ARUP Laboratories advises clinicians and families to find a board-certified genetic counselor through the National Society of Genetic Counselors' directory before ordering PSEN1-related testing, per ARUP's test directory. That directory search is a reasonable first step for a reader trying to find a referral, since many primary care offices and even neurology practices do not have a genetic counselor on staff.
Who Should Ask for This Test, and Who Shouldn't
The clearest candidates are people with dementia symptoms that began before age 65, especially when a parent or sibling was also diagnosed early. A family history that is simply unknown — common after adoption or family estrangement — also meets the criteria insurers and guidelines use, per Blue Shield of California's policy. People whose dementia symptoms began after 65, with no family pattern of early onset, generally fall outside what these policies cover, since the test is designed to find a rare inherited cause rather than screen typical late-onset Alzheimer's.
Insurers explicitly exclude general risk screening of asymptomatic adults from coverage, per Blue Cross NC's policy, so a healthy adult curious about their risk without a strong family history should expect resistance from a payer even if a lab will run the test out of pocket. A relative of someone with a confirmed PSEN1 mutation occupies a distinct category: predictive testing rather than diagnostic testing. That person is not yet symptomatic, so the decision carries different stakes, and the counseling protocol built for Huntington's disease exists precisely for this situation, per Alzforum's summary of the ACMG/NSGC guideline. Steps for starting the referral conversation:.
- Ask the treating neurologist or primary care physician whether early-onset criteria are documented in the chart.
- Request a referral to a genetic counselor before the blood draw, not after.
- Bring any known diagnoses or ages of onset for parents, siblings, or other blood relatives to that first counseling appointment.
Frequently Asked Questions
Does a negative PSEN1 test rule out a genetic cause of early-onset dementia?
No. A disease-causing variant is found in only 60% to 80% of people tested for early-onset Alzheimer's, per ARUP Laboratories, so a negative result can mean the cause lies in a gene not yet tested.
Is the PSEN1 test ever ordered by itself?
Labs typically run it as part of a panel with APP and PSEN2, since all three cause the same early-onset familial pattern, per UW Health's genetic-counseling presentation.
Will insurance cover testing for a healthy relative who just wants to know their risk?
Policies generally cover this only when the relative is at risk from a family member with a confirmed mutation, and require the Huntington's-style pre- and post-test counseling protocol, per Alzforum's summary of the ACMG/NSGC guideline.
